Search results for "Coagulant"

showing 10 items of 342 documents

Use of direct oral anticoagulants in very elderly patients: a case report of apixaban in an ultracentenary patient.

2019

no

Malemedicine.medical_specialtyPyridonesFrail ElderlyTreatment outcomeMEDLINEAdministration Oralanticoagulants elderlyAtrial FibrillationmedicineHumansFrail elderlyIntensive care medicineGeriatric AssessmentAged 80 and overbusiness.industryGeriatric assessmentGeneral MedicineSettore MED/11 - Malattie Dell'Apparato CardiovascolareChronic diseaseTreatment OutcomeChronic DiseasePyrazolesApixabanCardiology and Cardiovascular Medicinebusinessmedicine.drugFactor Xa InhibitorsJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: A randomized trial

2009

BACKGROUND: Low-dose oral vitamin K decreases the international normalized ratio (INR) in overanticoagulated patients who receive warfarin therapy. Its effects on bleeding events are uncertain. OBJECTIVE: To see whether low-dose oral vitamin K reduces bleeding events over 90 days in patients with warfarin-associated coagulopathy. DESIGN: Multicenter, randomized, placebo-controlled trial. Randomization was computer-generated, and participants were allocated to trial groups by using sequentially numbered study drug containers. Patients, caregivers, and those who assessed outcomes were blinded to treatment assignment. SETTING: 14 anticoagulant therapy clinics in Canada, the United States, and …

Malemedicine.medical_specialtyRandomizationVitamin Kmedicine.drug_classAdministration OralHemorrhageoral vitamin k anticoagulantsPlacebolaw.inventionSettore MED/15 - Malattie Del SanguePlacebosRandomized controlled trialOral administrationlawInternal medicineThromboembolismInternal MedicinemedicineOutpatient clinicHumansInternational Normalized RatioAgedAged 80 and overbusiness.industryAnticoagulantWarfarinAge FactorsAnticoagulantsGeneral MedicineMiddle AgedAntifibrinolytic AgentsSurgeryClinical trialTreatment OutcomeFemaleWarfarinbusinessmedicine.drug
researchProduct

Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation

2008

Aims: To gain insight in the prognosis and treatment of atrial fibrillation (AF) patients during 1-year follow-up in the Euro Heart Survey (EHS) on AF. Methods and results: The EHS enrolled 5333 AF patients in 2003-2004. One-year follow-up data were available for 80%. Of first detected AF patients, 46% did not have a recurrence during 1 year, paroxysmal AF largely remained paroxysmal AF (80%), and 30% of persistent AF progressed to permanent AF. Many treatment changes occurred since baseline. Oral anticoagulation was started in 19% and discontinued in 16% of all patients. Of patients initially on rhythm control 27% did not receive rhythm control during follow-up, whereas 15% of patients ini…

Malemedicine.medical_specialtyRate controlHeart DiseasesHeart diseasePrognosiHemorrhageRisk AssessmentAnticoagulationElectrocardiographyInternal medicineAtrial FibrillationHumansMedicineSinus rhythmProspective StudiesMortalityProspective cohort studyStrokeSurvival rateAgedProgressionmedicine.diagnostic_testbusiness.industryAnticoagulantAnticoagulantsAtrial fibrillationPrognosismedicine.diseaseManagementStrokeSurvival RateProspective StudieHeart DiseaseTreatment OutcomeHeart failureDisease ProgressionCardiologyRhythm controlFemaleCardiology and Cardiovascular MedicinebusinessElectrocardiographyHumanEuropean Heart Journal
researchProduct

Rivaroxaban-induced hepatotoxicity

2017

Aim/Objective/Background Direct-acting oral anticoagulant drugs are marketed worldwide for the primary and secondary prevention and treatment of thromboembolic disorders. Rivaroxaban, an oral, direct factor Xa inhibitor, is one of the most used. Rivaroxaban-induced hepatotoxicity is unusual, although a number of adverse reports have recently been reported. Here, we report two new cases of rivaroxaban-induced hepatitis. Methods A systematic search of case reports on the MEDLINE database encompassing the years 2008–2016 was carried out.Additional references were obtained following a manual search of the retrieved papers. We report two new cases of adverse events occurred in patients treated w…

Malemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.drug_mechanism_of_actionFactor Xa InhibitorMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRivaroxabanInternal medicinemedicineHumansAgedAged 80 and overSecondary preventionRivaroxabanHepatologybusiness.industryGastroenterologydrug-induced liver injury hepatotoxicity pharmacovigilancerivaroxabanOral anticoagulantFemale030211 gastroenterology & hepatologyChemical and Drug Induced Liver InjurybusinessFactor Xa Inhibitorsmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study

2021

Abstract Introduction A hypercoagulable condition was described in patients with coronavirus disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to disease progression and lethality. Aim We evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients. Methods In a retrospective observational study, 2,574 unselected patients hospitalized in 30 clinical centers in Italy from February 19, 2020 to June 5, 2020 with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection were analyzed. The primary endpoint in a time-to event analysis was in-hospital death, comparing patients who receive…

Malemedicine.medical_specialtySettore MED/17 - Malattie Infettivecoronavirusheparin030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineClinical endpointmedicineHumansThrombophilia030212 general & internal medicineHospital MortalityBlood CoagulationSurvival analysisAgedRetrospective Studiestreatmentbusiness.industryHeparinMortality rateCOVID-19mortalityLow-Molecular-WeightAnticoagulantsCOVID-19Retrospective cohort studyHeparinHematologyHeparin Low-Molecular-WeightMiddle AgedmortalitySurvival AnalysisCOVID-19 Drug Treatmentcoagulation activationcoronaviruItalytreatmentsPropensity score matchingcoagulation activation; coronavirus; COVID-19; heparin; mortality; treatmentsFemalecoagulation activation; coronavirus; COVID-19; heparin; mortality; treatments; Aged; Anticoagulants; Blood Coagulation; COVID-19; Female; Heparin; Heparin Low-Molecular-Weight; Hospital Mortality; Humans; Italy; Male; Middle Aged; Retrospective Studies; Survival Analysis; Thrombophiliabusinessmedicine.drug
researchProduct

Ischemic Stroke With Atrial Fibrillation: Characteristics and Time Trends 2006 to 2017 in the Dijon Stroke Registry.

2021

Background and Purpose: Because of the aging population, an increase in the prevalence of atrial fibrillation (AF) is currently observed, thus leading to a rise in AF-related ischemic stroke (IS). We analyzed the current prevalence of AF among patients with IS, their characteristics, and temporal trends from 2006 to 2017 in the population-based Dijon Stroke Registry. Methods: We used data from the Dijon Stroke Registry, an ongoing population-based study that records all cases of acute stroke among residents of the city of Dijon. All patients with IS between 2006 and 2017 were included. Previous AF was defined if it was mentioned in the medical file before stroke and newly diagnosed AF if i…

Malemedicine.medical_specialtyStroke registryPopulationAdministration OralSex FactorsInternal medicineAtrial FibrillationMedicineHumansIn patientRegistrieseducationStrokeAgedIschemic StrokeAdvanced and Specialized Nursingeducation.field_of_studybusiness.industryTime trendsStroke scaleAge FactorsAnticoagulantsAtrial fibrillationMiddle Agedmedicine.diseaseIschemic strokeFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessStroke
researchProduct

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct

Pulmonary embolism: risk assessment and management.

2012

Acute pulmonary embolism (PE) poses a significant burden on health and survival. Its severity ranges from asymptomatic, incidentally discovered subsegmental thrombi to massive, pressor-dependent PE complicated by cardiogenic shock and multisystem organ failure. Rapid and accurate risk stratification is therefore of paramount importance to ensure the highest quality of care. This article critically reviews currently available and emerging tools for risk-stratifying acute PE, and particularly for distinguishing between elevated (intermediate) and low risk among normotensive patients. We focus on the potential value of risk assessment strategies for optimizing severity-adjusted management. Apa…

Malemedicine.medical_specialtyVena Cava FiltersVitamin Kmedicine.medical_treatmentEarly TherapyRisk AssessmentSeverity of Illness IndexRecurrenceSeverity of illnessmedicineAmbulatory CareHumansThrombolytic TherapyIntensive care medicineAgedRandomized Controlled Trials as TopicThrombectomybusiness.industryHeparinCardiogenic shockAnticoagulantsThrombolysisLength of StayMiddle Agedmedicine.diseasePrognosisPulmonary embolismCardiac Imaging TechniquesEmbolismAcute DiseaseFemaleCardiology and Cardiovascular MedicineMultiple organ dysfunction syndromeRisk assessmentbusinessPulmonary EmbolismBiomarkersEuropean heart journal
researchProduct

Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national…

2021

Abstract Aims Vitamin K antagonists (VKAs) are effective drugs reducing the risk for stroke in atrial fibrillation (AF), but the benefits derived from such therapy depend on the international normalized ratio (INR) maintenance in a narrow therapeutic range. Here, we aimed to determine independent variables driving poor anticoagulation control [defined as a time in therapeutic range (TTR) &amp;lt;65%] in a ‘real world’ national cohort of AF patients. Methods and results The SULTAN registry is a multicentre, prospective study, involving patients with non-valvular AF from 72 cardiology units expert in AF in Spain. At inclusion, all patients naïve for oral anticoagulation were started with VKAs…

Malemedicine.medical_specialtyVitamin K030204 cardiovascular system & hematologyAmiodaroneCoronary artery disease03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineAtrial FibrillationHumansMedicineInternational Normalized RatioProspective StudiesRegistries030212 general & internal medicineProspective cohort studyStrokeAgedAged 80 and overbusiness.industryProportional hazards modelAnticoagulantsAtrial fibrillationOdds ratioMiddle Agedmedicine.diseaseConfidence intervalStrokeFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEP Europace
researchProduct

Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists.

2018

BACKGROUND Although polypharmacy is associated with a negative clinical outcome in various settings and commonly observed in patients receiving oral anticoagulation therapy, evidence on the relevance for the clinical outcome of anticoagulated patients is currently limited. The aim of the study was to investigate the effect of polypharmacy on the clinical outcomes among patients taking phenprocoumon. DESIGN Prospective cohort study. SETTING Regular medical care. PARTICIPANTS Information on 2011 individuals receiving vitamin K antagonists was available for analysis from the prospective multicenter thrombEVAL study. MEASUREMENTS Data were obtained from clinical visits, computer-assisted interv…

Malemedicine.medical_specialtyVitamin KAdministration OralHemorrhage030204 cardiovascular system & hematologyPhenprocoumonCohort Studies03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineGermanyPrevalenceMedicineHumansCumulative incidenceDrug Interactions030212 general & internal medicineInternational Normalized RatioMultiple Chronic ConditionsProspective StudiesRisk factorMortalityProspective cohort studyAdverse effectAgedPolypharmacybusiness.industryMedical recordHazard ratioAnticoagulantsHospitalizationPolypharmacyFemaleGeriatrics and GerontologyDrug Monitoringbusinessmedicine.drugJournal of the American Geriatrics Society
researchProduct